NASDAQ:AMAG - AMAG Pharmaceuticals Stock Price, Price Target & More

$19.35 -0.50 (-2.52 %)

(As of 04/22/2018 04:00 PM ET)

Previous Close$19.35

Today's Range$19.00 - $19.95

52-Week Range$11.93 - $24.85

Volume527,492 shs

Average Volume759,463 shs

Market Capitalization$659.62 million

P/E Ratio-3.39

Dividend YieldN/A

Beta0.09

About AMAG Pharmaceuticals (NASDAQ:AMAG)

AMAG Pharmaceuticals, Inc., a biopharmaceutical company, manufactures, develops, and commercializes therapeutics for maternal and women's health, anemia management, and cancer supportive care in the United States. It markets Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Feraheme (ferumoxytol), an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, as well as patients who have chronic kidney disease; Intrarosa(prasterone) vaginal insert steroid for the treatment of dyspareunia due to menopause; and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucocitis/stomatiits and various types of oral wounds. The company also offers Cord Blood Registry services that are related to the collection, processing, and storage of umbilical cord blood and cord tissue units for pregnant women and their families. In addition, it has an option agreement with Velo Bio LLC to acquire the rights to digoxin immune fab, a polyclonal antibody, which is in Phase IIb/IIIa trial for the treatment of severe preeclampsia in pregnant women. The company sells Feraheme to authorized wholesalers and specialty distributors. It has a license agreement with Palatin Technologies, Inc. to research, develop, and commercialize Bremelanotide, an investigational product for the treatment of hypoactive sexual desire disorder (HSDD) in pre-menopausal women, as well as with Endoceutics, Inc. to develop and commercialize pharmaceutical products with dehydroepiandrosterone; and development and license agreement with Antares Pharma, Inc. to develop, use, sell, offer for sale, and import and export the Makena auto-injector. AMAG Pharmaceuticals, Inc. was founded in 1981 and is headquartered in Waltham, Massachusetts.

Receive AMAG News and Ratings via Email

Sign-up to receive the latest news and ratings for AMAG and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations

Sub-IndustryBiotechnology

SectorMedical

SymbolNASDAQ:AMAG

CUSIP00163U10

Webwww.amagpharma.com

Phone617-498-3300

Debt

Debt-to-Equity Ratio0.93%

Current Ratio1.74%

Quick Ratio1.60%

Price-To-Earnings

Trailing P/E Ratio-3.39

Forward P/E Ratio-5.95

P/E GrowthN/A

Sales & Book Value

Annual Sales$609.95 million

Price / Sales1.08

Cash FlowN/A

Price / CashN/A

Book Value$22.34 per share

Price / Book0.87

Profitability

EPS (Most Recent Fiscal Year)($5.71)

Net Income$-199,220,000.00

Net Margins-32.66%

Return on Equity0.96%

Return on Assets0.39%

Miscellaneous

Employees762

Outstanding Shares34,090,000

How to Become a New Pot Stock Millionaire

AMAG Pharmaceuticals (NASDAQ:AMAG) Frequently Asked Questions

What is AMAG Pharmaceuticals' stock symbol?

AMAG Pharmaceuticals trades on the NASDAQ under the ticker symbol "AMAG."

How were AMAG Pharmaceuticals' earnings last quarter?

AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) posted its quarterly earnings data on Tuesday, February, 27th. The specialty pharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.58) by $0.68. The specialty pharmaceutical company had revenue of $158.30 million for the quarter, compared to the consensus estimate of $158.84 million. AMAG Pharmaceuticals had a negative net margin of 32.66% and a positive return on equity of 0.96%. The business's revenue for the quarter was up 4.4% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.31) EPS. View AMAG Pharmaceuticals' Earnings History.

When is AMAG Pharmaceuticals' next earnings date?

AMAG Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, April, 30th 2018. View Earnings Estimates for AMAG Pharmaceuticals.

What price target have analysts set for AMAG?

11 Wall Street analysts have issued 12 month price objectives for AMAG Pharmaceuticals' shares. Their predictions range from $17.00 to $45.00. On average, they expect AMAG Pharmaceuticals' share price to reach $24.20 in the next twelve months. View Analyst Ratings for AMAG Pharmaceuticals.

What are Wall Street analysts saying about AMAG Pharmaceuticals stock?

Here are some recent quotes from research analysts about AMAG Pharmaceuticals stock:

1. Cantor Fitzgerald analysts commented, "Makena autoinjector moving to launch pad. On today’s call, management commented that the autoinjector would be launched by the end of March. Pre- launch activities include the critical element of providing patient access to the drug. We believe it possible that the switch to the autoinjector could be facilitated through modulating the Makena vial (IM administration) inventory." (2/27/2018)
2. According to Zacks Investment Research, "AMAG reported earnings of $1.57 in the third quarter of 2017 as against the Zacks Consensus Estimate of a loss. However, the company missed the same on revenues. AMAG lowered its total revenue guidance for 2017. Furthermore, the termination of the licensing agreement with Takeda for Feraheme in ex-U.S. territories was a major setback for the company. So far this year, AMAG’s shares have underperformed the industry. Nevertheless, the company is working towards label expansion of Feraheme, and potential approval and launch of the Makena subcutaneous auto-injector (SQ) AMAG also remains focused on expanding Makena’s label further in a bid to increase its market share." (11/8/2017)

Who are some of AMAG Pharmaceuticals' key competitors?

Some companies that are related to AMAG Pharmaceuticals include Myovant Sciences (MYOV), G1 Therapeutics (GTHX), TherapeuticsMD (TXMD), Apellis Pharmaceuticals (APLS), Endo International (ENDP), WAVE Life Sciences (WVE), Theravance Biopharma (TBPH), PTC Therapeutics (PTCT), Mallinckrodt (MNK), Revance Therapeutics (RVNC), Dynavax Technologies (DVAX), Epizyme (EPZM), TG Therapeutics (TGTX), Retrophin (RTRX), Intra-Cellular Therapies (ITCI), CytomX Therapeutics (CTMX), Athenex (ATNX) and Zai Lab (ZLAB).

Who are AMAG Pharmaceuticals' key executives?

AMAG Pharmaceuticals' management team includes the folowing people:

Dr. William K. Heiden, CEO & Director (Age 58)
Mr. Edward H. Myles MBA, Exec. VP & CFO (Age 46)
Mr. Joseph D. Vittiglio Esq., Exec. VP of Quality, Gen. Counsel & Sec. (Age 46)
Dr. Julie Krop M.D., Exec. VP & Chief Medical Officer (Age 52)
Mr. Nicholas Grund, Exec. VP & Chief Commercial Officer (Age 48)

Has AMAG Pharmaceuticals been receiving favorable news coverage?

News articles about AMAG stock have trended somewhat positive recently, Accern Sentiment Analysis reports. Accern identifies negative and positive media coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. AMAG Pharmaceuticals earned a news sentiment score of 0.11 on Accern's scale. They also assigned news headlines about the specialty pharmaceutical company an impact score of 46.18 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the next few days.

How do I buy shares of AMAG Pharmaceuticals?

Shares of AMAG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is AMAG Pharmaceuticals' stock price today?

One share of AMAG stock can currently be purchased for approximately $19.35.

How big of a company is AMAG Pharmaceuticals?

AMAG Pharmaceuticals has a market capitalization of $659.62 million and generates $609.95 million in revenue each year. The specialty pharmaceutical company earns $-199,220,000.00 in net income (profit) each year or ($5.71) on an earnings per share basis. AMAG Pharmaceuticals employs 762 workers across the globe.

How can I contact AMAG Pharmaceuticals?

AMAG Pharmaceuticals' mailing address is 1100 WINTER STREET, WALTHAM MA, 02451. The specialty pharmaceutical company can be reached via phone at 617-498-3300 or via email at [email protected]

MarketBeat Community Rating for AMAG Pharmaceuticals (AMAG)

Community Ranking:		2.2 out of 5 ( )
Outperform Votes:		272 (Vote Outperform)
Underperform Votes:		353 (Vote Underperform)
Total Votes:		625

MarketBeat's community ratings are surveys of what our community members think about AMAG Pharmaceuticals and other stocks. Vote "Outperform" if you believe AMAG will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AMAG will underperform the S&P 500 over the long term. You may vote once every thirty days.

AMAG Pharmaceuticals (NASDAQ:AMAG) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

11 Wall Street analysts have issued ratings and price targets for AMAG Pharmaceuticals in the last 12 months. Their average twelve-month price target is $24.20, suggesting that the stock has a possible upside of 25.06%. The high price target for AMAG is $45.00 and the low price target for AMAG is $17.00. There are currently 9 hold ratings and 2 buy ratings for the stock, resulting in a consensus rating of "Hold."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Hold	Hold	Hold	Hold
Consensus Rating Score:	2.18	2.18	2.25	2.14
Ratings Breakdown:	0 Sell Rating(s) 9 Hold Rating(s) 2 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 9 Hold Rating(s) 2 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 9 Hold Rating(s) 3 Buy Rating(s) 0 Strong Buy Rating(s)	1 Sell Rating(s) 10 Hold Rating(s) 3 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$24.20	$24.20	$21.00	$27.4167
Price Target Upside:	25.06% upside	20.40% upside	58.49% upside	75.75% upside

AMAG Pharmaceuticals (NASDAQ:AMAG) Consensus Price Target History

Price Target History for AMAG Pharmaceuticals (NASDAQ:AMAG)

AMAG Pharmaceuticals (NASDAQ:AMAG) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
3/14/2018	B. Riley	Boost Price Target	Neutral -> Neutral	$16.00 -> $23.00	Medium
3/5/2018	Jefferies Group	Downgrade	Buy -> Hold	$21.00 -> $20.00	Low
3/1/2018	Piper Jaffray	Reiterated Rating	Hold	$20.00	Medium
2/28/2018	Morgan Stanley	Boost Price Target	Overweight -> Overweight	$22.00 -> $24.00	Medium
2/27/2018	Cowen	Reiterated Rating	Hold	$25.00	Medium
2/27/2018	Cantor Fitzgerald	Reiterated Rating	Hold	$17.00	Medium
2/15/2018	Janney Montgomery Scott	Upgrade	Neutral -> Buy	$16.65 -> $45.00	High
2/2/2018	Leerink Swann	Reiterated Rating	Market Perform		High
8/31/2017	Deutsche Bank	Reiterated Rating	Hold	$24.00	Low
7/7/2017	Citigroup	Lower Price Target	Hold	$24.00	Low
6/1/2017	Barclays	Reiterated Rating	Equal Weight	$25.00 -> $20.00	Low
2/2/2017	Guggenheim	Lower Price Target	Buy	$42.00 -> $28.00	N/A
1/31/2017	JPMorgan Chase	Set Price Target	Hold	$24.00	N/A
1/11/2017	Needham & Company LLC	Downgrade	Buy -> Hold		N/A
1/9/2017	Raymond James	Reiterated Rating	Market Perform -> Underperform		N/A

(Data available from 4/22/2016 forward)

AMAG Pharmaceuticals (NASDAQ:AMAG) Earnings History and Estimates Chart

Earnings by Quarter for AMAG Pharmaceuticals (NASDAQ:AMAG)

AMAG Pharmaceuticals (NASDAQ:AMAG) Earnings Estimates

2018 EPS Consensus Estimate: ($3.97)

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2018	3	($0.80)	($0.08)	($0.35)
Q2 2018	2	($0.68)	($0.02)	($0.35)
Q3 2018	2	($2.13)	($0.57)	($1.35)
Q4 2018	2	($2.40)	($1.44)	($1.92)

AMAG Pharmaceuticals (NASDAQ AMAG) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
4/30/2018		($0.24)					N/A
2/27/2018	Q4 2017	($0.58)	$0.10	$158.84 million	$158.30 million	View	N/A
11/2/2017	Q3 2017	($0.04)	$1.57	$166.83 million	$153.74 million	View	N/A
8/3/2017	Q2 2017	($0.58)	($0.40)	$158.83 million	$158.39 million	View	Listen
5/2/2017	Q1 2017	$0.09	($1.06)	$150.32 million	$139.47 million	View	Listen
2/14/2017	Q416	$0.24	($0.31)	$155.12 million	$151.60 million	View	Listen
11/3/2016	Q316	$1.50	$1.78	$141.65 million	$143.80 million	View	Listen
8/9/2016	Q216	$1.20	$1.45	$128.52 million	$127.40 million	View	Listen
5/3/2016	Q116	$1.11	$0.94	$124.83 million	$117.60 million	View	Listen
2/17/2016	Q415	$1.16	$1.12	$120.13 million	$108.70 million	View	Listen
11/3/2015	Q315	$1.21	($0.62)	$113.88 million	$103.50 million	View	Listen
7/23/2015	Q215	$0.75	$1.12	$94.05 million	$123.90 million	View	Listen
5/5/2015	Q115	$1.04	$1.11	$84.66 million	$89.50 million	View	Listen
2/9/2015	Q4 2014	$0.30	$0.04	$53.94 million	$53.25 million	View	N/A
10/30/2014	Q314	($0.08)	$0.06	$26.30 million	$25.50 million	View	Listen
7/29/2014	Q214	($0.09)	($0.07)	$23.40 million	$24.80 million	View	Listen
4/24/2014	Q1	($0.07)	($0.33)	$22.73 million	$20.80 million	View	Listen
2/6/2014	Q4	($0.10)	($0.17)	$21.01 million	$21.70 million	View	Listen
10/17/2013	Q313	($0.12)	($0.01)	$20.37 million	$21.60 million	View	Listen
8/1/2013	Q2 2013	($0.17)	($0.09)	$18.51 million	$19.60 million	View	Listen
4/23/2013	Q1 2013	($0.20)	($0.18)	$17.99 million	$17.90 million	View	Listen
3/1/2013	Q4 2012	($0.06)	($0.17)	$22.54 million	$21.14 million	View	N/A
11/1/2012	Q312	($0.26)	($0.19)	$20.43 million	$17.70 million	View	N/A
7/26/2012		($0.39)	$0.16			View	N/A
5/1/2012		($0.63)	($0.58)			View	N/A
3/5/2012		($1.09)	($0.87)			View	N/A
11/4/2011		($0.98)	($0.78)			View	N/A
7/26/2011	Q2 2011	($1.08)	($0.92)			View	N/A
5/3/2011		($0.99)	($1.05)			View	N/A
2/25/2011		($1.04)	($0.94)			View	N/A
10/28/2010	Q3 2010	($1.09)	($0.81)			View	N/A
7/28/2010	Q2 2010	($0.97)	($1.02)			View	N/A
4/27/2010	Q1 2010	($0.84)	($1.15)			View	N/A
3/1/2010	Q4 2009	($1.08)	($1.07)			View	N/A
10/29/2009	Q3 2009	($1.45)	($1.29)			View	N/A
7/29/2009	Q2 2009	($1.53)	($1.55)			View	N/A
4/30/2009	Q1 2009	($1.30)	($1.55)			View	N/A
2/27/2009	Q4 2008	($1.40)	($1.28)			View	N/A
11/3/2008	Q3 2008	($1.12)	($1.39)			View	N/A
7/29/2008	Q2 2008	($0.62)	($1.00)			View	N/A
4/25/2008	Q1 2008	($0.60)	($0.55)			View	N/A
2/21/2008	Q4 2007	($0.53)	($0.57)			View	N/A

(Earnings results data provided by Zacks Investment Research)

AMAG Pharmaceuticals (NASDAQ:AMAG) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date

(Data available from 1/1/2013 forward)

AMAG Pharmaceuticals (NASDAQ AMAG) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 3.80%

Insider Trading History for AMAG Pharmaceuticals (NASDAQ:AMAG)

Institutional Ownership by Quarter for AMAG Pharmaceuticals (NASDAQ:AMAG)

AMAG Pharmaceuticals (NASDAQ AMAG) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/6/2018	Joseph Vittiglio	EVP	Sell	770	$20.80	$16,016.00	32,635
8/29/2017	Joseph Vittiglio	SVP	Sell	1,250	$16.75	$20,937.50	33,504
7/13/2017	Julie Krop	SVP	Sell	4,938	$20.00	$98,760.00	28,336
5/1/2017	Julie Krop	SVP	Sell	1,891	$24.45	$46,234.95	36,777
10/20/2016	Julie Krop	SVP	Sell	4,938	$24.80	$122,462.40	23,668
11/10/2015	John A Fallon	Director	Buy	3,230	$31.20	$100,776.00	6,086
10/1/2015	William K Heiden	CEO	Sell	2,000	$39.69	$79,380.00	200,721
9/1/2015	William K Heiden	CEO	Sell	2,000	$61.19	$122,380.00	202,721
7/15/2015	William K Heiden	CEO	Sell	20,000	$75.00	$1,500,000.00
6/15/2015	Scott A Holmes	SVP	Sell	7,580	$66.63	$505,055.40
6/5/2015	William K Heiden	CEO	Sell	66,875	$69.90	$4,674,562.50
6/4/2015	Frank E Thomas	COO	Sell	20,000	$69.47	$1,389,400.00
6/3/2015	Scott A Holmes	SVP	Sell	22,516	$68.88	$1,550,902.08
1/9/2015	Adage Capital Partners Gp Llc	Major Shareholder	Sell	1,250,000	$46.49	$58,112,500.00
1/9/2014	Christopher White	Insider	Sell	4,000	$22.37	$89,480.00	24,834
1/7/2014	Christopher White	Insider	Sell	5,000	$23.90	$119,500.00	28,834

(Data available from 1/1/2013 forward)

AMAG Pharmaceuticals (NASDAQ AMAG) News Headlines

Source:

Date	Headline
	AMAG Pharmaceuticals (AMAG) Downgraded by BidaskClub www.americanbankingnews.com - April 21 at 7:06 AM
	$155.89 Million in Sales Expected for AMAG Pharmaceuticals, Inc. (AMAG) This Quarter www.americanbankingnews.com - April 17 at 3:44 AM
	AMAG Pharmaceuticals, Inc. Expected to Post FY2020 Earnings of ($1.47) Per Share (AMAG) www.americanbankingnews.com - April 16 at 3:03 AM
	AMAG Pharmaceuticals (AMAG) Upgraded to Sell at ValuEngine www.americanbankingnews.com - April 16 at 12:19 AM
	-$0.48 EPS Expected for AMAG Pharmaceuticals, Inc. (AMAG) This Quarter www.americanbankingnews.com - April 15 at 11:11 AM
	Edited Transcript of AMAG presentation 8-Mar-17 3:25pm GMT finance.yahoo.com - April 12 at 5:44 PM
	AMAG Pharmaceuticals, Inc. (AMAG) Given Consensus Recommendation of "Hold" by Analysts www.americanbankingnews.com - April 12 at 1:43 PM
	AMAG Pharmaceuticals (AMAG) Stock Rating Lowered by BidaskClub www.americanbankingnews.com - April 10 at 10:30 PM
	Reader Inquiry: Antares Pharma PDUFA Date In September, Is The Stock A Buy Here? seekingalpha.com - April 10 at 8:18 AM
	Janney Montgomery Scott Reaffirms Hold Rating for AMAG Pharmaceuticals (AMAG) www.americanbankingnews.com - April 6 at 10:54 PM
	AMAG Pharmaceuticals (AMAG) Downgraded to Hold at Zacks Investment Research www.americanbankingnews.com - April 6 at 9:16 PM
	AMAG Pharmaceuticals (AMAG) Upgraded to Buy by BidaskClub www.americanbankingnews.com - April 6 at 11:59 AM
	AMAG Pharmaceuticals (AMAG) Earns Neutral Rating from Analysts at Piper Jaffray www.americanbankingnews.com - April 6 at 11:31 AM
	AMAG Pharmaceuticals (AMAG) Stock Rating Lowered by Zacks Investment Research www.americanbankingnews.com - April 5 at 7:58 PM
	CRISPR Therapeutics Announces the Appointment of Steve Caffé as Head of Regulatory Affairs globenewswire.com - April 4 at 4:19 PM
	AMAG Pharmaceuticals (AMAG) Upgraded to "Hold" at Zacks Investment Research www.americanbankingnews.com - April 1 at 12:40 AM
	AMAG Pharmaceuticals (AMAG) Lifted to Hold at ValuEngine www.americanbankingnews.com - March 31 at 1:05 PM
	AMAG Pharmaceuticals, Inc. (AMAG) Expected to Announce Quarterly Sales of $155.89 Million www.americanbankingnews.com - March 31 at 2:44 AM
	AMAG Pharma (AMAG) Down 10.6% Since Earnings Report: Can It Rebound? finance.yahoo.com - March 29 at 5:35 PM
	Zacks: Brokerages Anticipate AMAG Pharmaceuticals, Inc. (AMAG) to Post -$0.48 Earnings Per Share www.americanbankingnews.com - March 29 at 3:14 PM
	AMAG Pharmaceuticals (AMAG) Presents At Needham And Company 17th Annual Healthcare Conference - Slideshow seekingalpha.com - March 29 at 8:19 AM
	B. Riley Reiterates Hold Rating for AMAG Pharmaceuticals (AMAG) www.americanbankingnews.com - March 28 at 12:58 PM
	BRIEF-AMAG Pharmaceuticals Submits NDA To FDA For Bremelanotide www.reuters.com - March 27 at 5:19 PM
	AMAG Pharma files U.S. marketing application for HSDD med bremelanotide seekingalpha.com - March 27 at 5:19 PM
	AMAG Pharmaceuticals (AMAG) Upgraded to Sell at BidaskClub www.americanbankingnews.com - March 26 at 5:58 PM
	AMAG Pharma (AMAG) Submits NDA to FDA for Bremelanotide for Treatment of Hypoactive Sexual Desire Disorder ... www.streetinsider.com - March 26 at 5:24 PM
	Palatin Technologies Announces Submission of Bremelanotide NDA to FDA for Treatment of Hypoactive Sexual Desire ... www.prnewswire.com - March 26 at 5:24 PM
	AMAG Pharmaceuticals Submits a New Drug Application to the US Food and Drug Administration for Bremelanotide for ... globenewswire.com - March 26 at 5:24 PM
	Palatin Technologies Announces Submission of Bremelanotide NDA to FDA for Treatment of Hypoactive Sexual Desire Disorder (HSDD) in Premenopausal Women finance.yahoo.com - March 26 at 8:16 AM
	AMAG Pharmaceuticals Submits a New Drug Application to the U.S. Food and Drug Administration for Bremelanotide for the treatment of Hypoactive Sexual Desire Disorder (HSDD) in Premenopausal Women finance.yahoo.com - March 26 at 8:16 AM
	AMAG Pharmaceuticals (AMAG) Stock Rating Lowered by ValuEngine www.americanbankingnews.com - March 25 at 9:16 PM
	AMAG Pharmaceuticals (AMAG) Upgraded by ValuEngine to "Hold" www.americanbankingnews.com - March 24 at 8:54 PM
	Form 8-K AMAG PHARMACEUTICALS For: Mar 23 www.streetinsider.com - March 24 at 5:20 PM
	Form 8-K AMAG PHARMACEUTICALS For: Mar 23 - StreetInsider.com www.streetinsider.com - March 24 at 8:44 AM
	AMAG Pharmaceuticals Target of Unusually High Options Trading (AMAG) www.americanbankingnews.com - March 23 at 7:08 AM
	AMAG Pharmaceuticals, Inc. (AMAG) Given Average Recommendation of "Hold" by Brokerages www.americanbankingnews.com - March 18 at 1:50 PM
	AMAG Pharmaceuticals, Inc. (AMAG) Forecasted to Earn Q1 2018 Earnings of ($0.18) Per Share www.americanbankingnews.com - March 16 at 8:52 AM
	AMAG Pharmaceuticals (AMAG) PT Raised to $23.00 www.americanbankingnews.com - March 14 at 5:27 PM
	Autodesk, SCANA, And 3 Other Stocks With Clear Trading Opportunities This Week www.benzinga.com - March 13 at 7:23 PM
	-$0.58 Earnings Per Share Expected for AMAG Pharmaceuticals, Inc. (AMAG) This Quarter www.americanbankingnews.com - March 12 at 1:44 PM
	AMAG Pharmaceuticals (AMAG) Cut to Hold at BidaskClub www.americanbankingnews.com - March 10 at 9:45 AM
	Form 4 AMAG PHARMACEUTICALS For: Mar 02 Filed by: Bolgiano Elizabeth Scott www.streetinsider.com - March 7 at 6:40 PM
	AMAG Pharmaceuticals, Inc. (AMAG) Expected to Post Q1 2018 Earnings of ($0.08) Per Share www.americanbankingnews.com - March 7 at 8:16 AM
	Antares Pharma: Building Momentum To 2018 Profitability - Antares ... - Seeking Alpha seekingalpha.com - March 7 at 8:11 AM
	AMAG Pharmaceuticals, Inc. (AMAG) EVP Joseph Vittiglio Sells 770 Shares www.americanbankingnews.com - March 6 at 9:58 PM
	Premarket analyst action - healthcare - AMAG Pharmaceuticals, Inc ... - Seeking Alpha seekingalpha.com - March 6 at 8:10 AM
	Jefferies Group Lowers AMAG Pharmaceuticals (AMAG) to Hold www.americanbankingnews.com - March 5 at 5:34 PM
	AMAG Pharmaceuticals to Present at Upcoming Investor Conferences finance.yahoo.com - March 5 at 8:12 AM
	Bogle Investment Management L P DE Acquires Shares of 328,455 AMAG Pharmaceuticals, Inc. (AMAG) www.americanbankingnews.com - March 4 at 4:58 AM
	Spark Investment Management LLC Invests $1.55 Million in AMAG Pharmaceuticals, Inc. (AMAG) Stock www.americanbankingnews.com - March 3 at 12:36 PM

AMAG Pharmaceuticals (NASDAQ:AMAG) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

AMAG Pharmaceuticals (NASDAQ:AMAG) Income Statement, Balance Sheet and Cash Flow Statement

AMAG Pharmaceuticals (NASDAQ AMAG) Stock Chart for Sunday, April, 22, 2018

Loading chart…

This page was last updated on 4/22/2018 by MarketBeat.com Staff